SEARCH

SEARCH BY CITATION

References

  • Basco LK, Bickii J & Ringwald P (1998) In vitro activity of lumefantrine (benflumetol) against clinical isolates of Plasmodium falciparum in Yaounde, Cameroon. Antimicrobial Agents and Chemotherapy 42, 23472351.
  • Contamin H, Fandeur T, Bonnefoy S et al. (1995) PCR typing of field isolates of Plasmodium falciparum. Journal of Clinical Microbiology 33, 944951.
  • Desjardins RE, Canfield CJ, Haynes JD et al. (1979) Quantitative assessment of antimalarial activity in vitro by a semiautomated microdilution technique. Antimicrobial Agents and Chemotherapy 16, 710718.
  • Eyles DE, Hoo CC, Warren MC et al. (1963) Plasmodium falciparum resistant to chloroquine in Cambodia. American Journal of Tropical Medicine and Hygiene 12, 840843.
  • Ezzet F, Mull R & Karbwang J (1998) Population pharmacokinetics and therapeutic response of CGP 56697 (artemether + benflumetol) in malaria patients. British Journal of Clinical Pharmacology 46, 553561.
  • Giboda M & Denis MB (1988) Response of Kampuchean strains of Plasmodium falciparum to antimalarials: in vivo assessment of quinine and quinine plus tetracycline; multiple drug resistance in vitro. Journal of Tropical Medicine and Hygiene 91, 205211.
  • Huong MN, Hewitt S, Davis TM et al. (2001) Resistance of Plasmodium falciparum to antimalarial drugs in a highly endemic area of southern Vietnam: a study in vivo and in vitro. Transactions of the Royal Society of Tropical Medicine and Hygiene 95, 325329.
  • Kshirsagar NA, Gogtay NJ, Moorthy NS et al. (2000) A randomized, double-blind, parallel-group, comparative safety, and efficacy trial of oral co-artemether versus oral chloroquine in the treatment of acute uncomplicated Plasmodium falciparum malaria in adults in India. American Journal of Tropical Medicine and Hygiene 62, 402408.
  • Lim P, Chim P, Sem R et al. (2005) In vitro monitoring of Plasmodium falciparum susceptibility to artesunate, mefloquine, quinine and chloroquine in Cambodia: 2001–2002. Acta Tropica 93, 3140.
  • Lindegardh N, Annerberg A, Blessborn D et al. (2005) Development and validation of a bioanalytical method using automated solid-phase extraction and LC-UV for the simultaneous determination of lumefantrine and its desbutyl metabolite in plasma. Journal of Pharmaceutical and Biomedical Analysis 37, 10811088.
  • Looareesuwan S, Wilairatana P, Chokejindachai W et al. (1999) A randomized, double-blind, comparative trial of a new oral combination of artemether and benflumetol (CGP 56697) with mefloquine in the treatment of acute Plasmodium falciparum malaria in Thailand. American Journal of Tropical Medicine and Hygiene 60, 238243.
  • Meek SR, Doberstyn EB, Gauzère BA et al. (1986) Treatment of falciparum malaria with quinine and tetracycline or combined mefloquine/sulfadoxine/pyrimethamine on the Thai–Kampuchean border. American Journal of Tropical Medicine and Hygiene 35, 246250.
  • Nosten F, Van Vugt M, Price R et al. (2000) Effects of artesunate–mefloquine combination on incidence of Plasmodium falciparum malaria and mefloquine resistance in western Thailand: a prospective study. Lancet 356, 297302.
  • Pilz JB, Wernsdorfer G, Sirichaisinthop J et al. (2004) In vitro sensitivity of Plasmodium falciparum to lumefantrine in north-western Thailand. Wiener Klinische Wochenschrift 116 (Suppl. 4), 4146.
  • Price RN, Uhlemann AC, Brockman A et al. (2004) Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number. Lancet 364, 438447.
  • Stohrer JM, Dittrich S, Thongpaseuth V et al. (2004) Therapeutic efficacy of artemether–lumefantrine and artesunate-mefloquine for treatment of uncomplicated Plasmodium falciparum malaria in Luang Namtha Province, Lao People's Democratic Republic. Tropical Medicine and International Health 9, 11751183.
  • Taylor WR, Rigal J & Olliaro PL (2003) Drug resistant falciparum malaria and the use of artesunate-based combinations: focus on clinical trials sponsored by TDR. Journal of Vector Borne Diseases 40, 6572.
  • Vugt MV, Wilairatana P, Gemperli B et al. (1999) Efficacy of six doses of artemether–lumefantrine (benflumetol) in multidrug-resistant Plasmodium falciparum malaria. American Journal of Tropical Medicine and Hygiene 60, 936942.
  • Van Vugt M, Looareesuwan S, Wilairatana P et al. (2000) Artemether–lumefantrine for the treatment of multidrug-resistant falciparum malaria. Transactions of the Royal Society of Tropical Medicine and Hygiene 94, 545548.
  • White NJ, Van Vugt M & Ezzet F (1999) Clinical pharmacokinetics and pharmacodynamics and pharmacodynamics of artemether–lumefantrine. Clinical Pharmacokinetics 37, 105125.
  • WHO (2001) Antimalarial Drug Combination Therapy. Report of a WHO Technical Consultation. (WHO/CDS/RBM/2001.35) World Health Organization, Geneva.
  • WHO (2003) Assessment and Monitoring of Antimalarial Drug Efficacy for the Treatment of Uncomplicated falciparum Malaria. (WHO/HTM/RBM/2003.50) World Health Organization, Geneva.
  • WHO (2005) Susceptibility of Plasmodium falciparum to Antimalarial Drugs. Report on Global Monitoring 1996–2004. (WHO/HTM/MAL/2005.1103) World Health Organization, Geneva.
  • Yang H, Liu D, Yang Y et al. (2003) Changes in susceptibility of Plasmodium falciparum to artesunate in vitro in Yunnan Province, China. Transactions of the Royal Society of Tropical Medicine and Hygiene 97, 226228.